Slingshot members are tracking this event:

Resubmitted New Drug Application for AstraZeneca's (AZN) ZS-9 in Hyperkalemia Accepted for Review by FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Resubmitted, New Drug Application, Zs-9, Hyperkalemia, Fda, Accepted